Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 359,374,432
  • Shares Outstanding, K 2,682,900
  • Annual Sales, $ 76,450 M
  • Annual Income, $ 1,300 M
  • 36-Month Beta 0.70
  • Price/Sales 4.70
  • Price/Cash Flow 14.00
  • Price/Book 5.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 2.03
  • Number of Estimates 8
  • High Estimate 2.06
  • Low Estimate 2.00
  • Prior Year 1.90
  • Growth Rate Est. (year over year) +6.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
132.23 +3.87%
on 10/12/18
143.13 -4.04%
on 09/21/18
-2.14 (-1.53%)
since 09/14/18
3-Month
125.12 +9.77%
on 07/20/18
143.13 -4.04%
on 09/21/18
+12.66 (+10.15%)
since 07/16/18
52-Week
118.62 +15.79%
on 05/29/18
148.32 -7.40%
on 01/17/18
+1.23 (+0.90%)
since 10/16/17

Most Recent Stories

More News
iCIMS Named No. 1 in Delivering the Best Candidate Experience in North America

iCIMS Inc., the leading provider of talent acquisition software, was ranked No. 1 among companies for delivering an outstanding candidate experience in the prestigious 2018 North American CandE Awards....

JNJ : 137.18 (+2.41%)
Prescription drugs, lower taxes, power J&J 3Q beat

A jump in prescription drug sales and a sharply reduced tax bill boosted Johnson & Johnson's third-quarter sales and profit, which beat Wall Street expectations.

JNJ : 137.18 (+2.41%)
Global stocks rise amid strong earnings reports

SINGAPORE (AP) — World stock markets were mostly higher Tuesday after strong earnings reports in the United States.

MS : 44.60 (+2.60%)
JNJ : 137.18 (+2.41%)
UNH : 269.15 (+3.42%)
MeiraGTx Enters Collaboration with Johnson & Johnson Innovation to Develop Regulatable Gene Therapy Treatment using MeiraGTx Riboswitch Technology

MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has entered into a research collaboration and evaluation agreement with Janssen...

JNJ : 137.18 (+2.41%)
MGTX : 14.65 (+4.61%)
Johnson & Johnson (JNJ) Surpasses Q3 Earnings and Revenue Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.99% and 2.19%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

JNJ : 137.18 (+2.41%)
Johnson & Johnson Reports 2018 Third-Quarter Results:

Johnson & Johnson (NYSE: JNJ) today announced sales of $20.3 billion for the third quarter of 2018, an increase of 3.6% as compared to the third quarter of 2017. Operational sales results increased 5.5%,...

JNJ : 137.18 (+2.41%)
Johnson & Johnson to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Johnson & Johnson (NYSE: ) will be discussing their earnings results in their 2018 Third Quarter Earnings to be held on October 16, 2018 at 8:30 AM Eastern...

JNJ : 137.18 (+2.41%)
JPMorgan, Wells Fargo, Citigroup, Johnson & Johnson, Netflix and Schlumberger are part of Zacks Earnings Preview

JPMorgan, Wells Fargo, Citigroup, Johnson & Johnson, Netflix and Schlumberger are part of Zacks Earnings Preview

NFLX : 335.75 (+0.79%)
C : 69.32 (+0.16%)
WFC : 52.58 (-1.24%)
JPM : 107.12 (+0.73%)
JNJ : 137.18 (+2.41%)
SLB : 59.87 (+0.54%)
Banks Provide Positive Start to Q3 Earnings Season

Banks Provide Positive Start to Q3 Earnings Season

NFLX : 335.75 (+0.79%)
JNJ : 137.18 (+2.41%)
SLB : 59.87 (+0.54%)
Banks Provide Positive Start to Q3 Earnings Season

Banks Provide Positive Start to Q3 Earnings Season

NFLX : 335.75 (+0.79%)
JNJ : 137.18 (+2.41%)
SLB : 59.87 (+0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 136.04
1st Resistance Point 135.00
Last Price 137.18
1st Support Level 133.21
2nd Support Level 132.46

See More

52-Week High 148.32
Last Price 137.18
Fibonacci 61.8% 136.97
Fibonacci 50% 133.47
Fibonacci 38.2% 129.97
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar